Hepatitis B Immunoglobulin discontinuation in long-term liver transplant patients.
Eva Maria TeegenEriselda KeshiYones SalimAllan GillespieAkylbek SaipbaevWenzel SchöningRobert ÖllingerJohann PratschkeDennis EurichPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2020)
HBIG withdrawal under continuation of oral NUC therapy is safe and not related to graft dysfunction, based on blood tests and histology. HBIG-free prophylaxis is not associated with a worse outcome and displays a financial relief as well as a logistic simplification during long-term follow-up.